stockro1
Oct 2, 7:54 AM
$IXHL The disconnect here is getting hard to ignore.
~
$41M market cap.
$68.4M unrestricted cash.
No debt.
And this isn’t a company waiting to start development.
IHL-42X:
• Previous Phase 2 produced statistically significant AHI reductions, with individual responses up to 83%
• FDA Fast Track
• US patent protection into 2040
• DReAMzz now actively dosing ~120 patients across 14 US sites
• Study designed to optimise the formulation before Phase 3
Yesterday’s Stonegate update summed up the transition perfectly: IXHL has moved from preparation to clinical execution.
The market is still pricing this like a distressed biotech while the balance sheet and lead asset tell a very different story.
Now execution matters. Enrollment, dose optimisation and the eventual Phase 3 pathway are the milestones to watch.
For me, this remains one of the more interesting asymmetric biotech setups out there.
1 replies
